|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Clinical Therapy Trials—Drug |
The New Approaches to Brain Tumor Therapy CNS Consortium, Department of Hematology-Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, 30322 (S.P.); The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 (S.D.B., S.A.G., J.D.F., K.A.C., M.A.C.); Department of Neuro-Oncology, M.D. Anderson Cancer Center, Houston, TX 77030 (M.R.G.); USA
2 Address correspondence to Surasak Phuphanich, The NABTT CNS Consortium, Cancer Research Building, Room G93, 1650 Orleans Street, Baltimore, MD 21231 USA (s_phuphanich{at}emoryhealthcare.org).
Abstract
We determined the maximum tolerated dose (MTD), toxicity profile, pharmacokinetic parameters, and preliminary efficacy data of oral sodium phenylbutyrate (PB) in patients with recurrent malignant gliomas. Twenty-three patients with supratentorial recurrent malignant gliomas were enrolled on this dose escalation trial. Four dose levels of PB were studied: 9, 18, 27, and 36 g/day. Data were collected to assess toxicity, response, survival, and pharmacokinetics. All PB doses of 9, 18, and 27 g/day were well tolerated. At 36 g/day, two of four patients developed dose-limiting grade 3 fatigue and somnolence. At the MTD of 27 g/day, one of seven patients developed reversible grade 3 somnolence. Median survival from time of study entry was 5.4 months. One patient had a complete response for five years, and no partial responses were noted, which yielded an overall response rate of 5%. Plasma concentrations of 706, 818, 1225, and 1605 µM were achieved with doses of 9, 18, 27, and 36 g/day, respectively. The mean value for PB clearance in this patient population was 22 liters/h, which is significantly higher than the 16 liters/h reported in patients with other malignancies who were not receiving P450 enzyme-inducing anticonvulsant drugs (P = 0.038). This study defines the MTD and recommended phase 2 dose of PB at 27 g/day for heavily pretreated patients with recurrent gliomas. The pharmacology of PB appears to be affected by concomitant administration of P450-inducing anticonvulsants.
References
Baker, M.J., Brem, S., Daniels, S., Sherman, B., and Phuphanich, S. (2002) Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate. J. Neurooncol. 59,239 -242.[CrossRef][Medline]
Batchelor, T.T., Gilbert, M.R., Supko, J.G., Carson, K.A., Nabors, L.B., Grossman, S.A., Lesser, G.J., Mikkelsen, T., and Phuphanich, S. (2004) Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11. Neuro-Oncol. 6,21 -27[Abstract]
Buckner, J.C., Malkin, M.G., Reed, E., Cascino, T.L., Reid, J.M., Ames, M.M., Tong, W.P., Lim, S., and Figg, W.D. (1999) Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin. Proc. 74,137 -145.[Abstract]
Carducci, M.A., Nelson, J.B., Chan-Tack, K.M., Ayyagari, S.R.,
Sweatt, W.H., Campbell, P.A., Nelson, W.G., and Simons, J.W.
(1996) Phenylbutyrate induces apoptosis in human prostate cancer
and is more potent than phenylacetate. Clin. Cancer
Res. 2,379
-387.
Carducci, M.A., Gilbert, J., Bowling, M.K., Noe, D., Eisenberger,
M.A., Sinibaldi, V., Zabelina, Y., Chen, T.L., Grochow, L.B., and Donehower,
R.C. (2001) A phase I clinical and pharmacological evaluation of
sodium phenylbutyrate on a 120-h infusion schedule. Clin. Cancer
Res. 7,3047
-3055.
Chang, S.M., Kuhn, J.G., Robins, H.I., Schold, S.C., Spence, A.M.,
Berger, M.S., Mehta, M.P., Bozik, M.E., Pollack, I., Schiff, D., Gilbert, M.,
Rankin, C., and Prados, M.D. (1999) Phase II study of
phenylacetate in patients with recurrent malignant glioma: A North American
Brain Tumor Consortium report. J. Clin. Oncol.
17,984
-990.
Dmitrovsky, E., Markman, M., and Marks, P.A. (1990) Clinical use of differentiating agents in cancer therapy. Cancer Chemother. Biol. Response Modif. 11,303 -320.[Medline]
Fetell, M.R., Grossman, S.A., Fisher, J.D., Erlanger, B., Rowinsky, E., Stockel, J., and Piantadosi, S. (1997) Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J. Clin. Oncol. 15,3121 -3128.[Abstract]
Gibaldi, M., and Perrier, D. (1982) Noncompartmental analysis based on statistical moment theory. Chapter 11 in Pharmacokinetics. New York: Marcel Dekker. pp.409 -417.
Gilbert, J., Baker, S.D., Bowling, M.K., Grochow, L., Figg, W.D.,
Zabelina, Y., Donehower, R.C., and Carducci, M.A. (2001) A phase
I dose escalation and bioavailability study of oral sodium phenylbutyrate in
patients with refractory solid tumor malignancies. Clin. Cancer
Res. 7,2292
-2300.
Gilbert, M.R., Supko, J.G., Batchelor, T., Lessor, G., Fisher,
J.D., Piantadosi, S., and Grossman, S.A. (2003) Phase I clinical
and pharmacokinetic study of irinotecan in adults with recurrent glioma.
Clin. Cancer Res. 9,2940
-2949.
Gore, S.D., Samid, D., and Weng, L.J. (1997a) Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin. Cancer Res. 3,1755 -1762.[Abstract]
Gore, S.D., Miller, C.B., Weng, L.J., Burks, K., Griffin, C.A., Chen, T.-L., Smith, V., Burke, P.J., Grever, M., and Rowinsky, E.K. (1997b) Clinical development of sodium phenylbutyrate as a putative differentiating agent in myeloid malignancies. Anticancer Res. 17,3938 (abstract 29).
Gore, S.D., Weng, L.J., Figg, W.D., Zhai, S. Donehower, R.C.,
Dover, G., Grever, M.R., Griffin, C., Grochow, L.B., Hawkins, A., Burks, K.,
Zabelena, Y., and Miller, C.B. (2002) Impact of prolonged
infusions of the putative differentiating agent sodium phenylbutyrate on
myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer
Res. 8,963
-970.
Grossman, S.A., Fisher, J.D., Piantadosi, S., and Brem, H. (1998a) The New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: Organization, objectives, and activities. Cancer Control 5,107 -114.[Web of Science][Medline]
Grossman, S.A., Hochberg, F., Fisher, J., Chen, T.L., Kim, L., Gregory, R., Grochow, L.B., and Piantadosi, S. (1998b) Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. Cancer Chemother. Pharmacol. 42,118 -126.[CrossRef][Web of Science][Medline]
Hudgins, W.R., Pineau, T., Sher, T., Gonzales, F.J., Myers, C.E., and Samid, D. (1994) Anticancer activity of phenylacetate and related aromatic fatty acids: Correlation with lipophilicity and capacity to activate nuclear receptor. Proc. Am. Assoc. Can. Res. 35, 391 (abstract 2332).
Kaplan, E.L., and Meier, P. (1958) Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53,457 -481.[CrossRef][Web of Science]
Samid, D., Shack, S., and Myers, C.E. (1993) Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. Clin. Invest. 91,2288 -2295.
Samid, D., Ram, Z., Hudgins, W.R., Shack, S., Liu, L., Walbridge,
S., Oldfield, E.H., and Myers, C.E. (1994) Selective activity of
phenylacetate against malignant gliomas: Resemblance to fetal brain damage in
phenylketonuria. Cancer Res.
54,891
-895.
Sidell, N., Wada, R., Han, G., Chang, B., Shack, S., Moore, T., and Samid, D. (1995) Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells. Int. J. Cancer 60,507 -514.[Web of Science][Medline]
Warrell, R.P., Jr., He, L.Z., Richon, V., Calleja, E., and
Pandolfi, P.P. (1998) Therapeutic targeting of transcription in
acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
J. Natl. Cancer Inst.
90,1621
-1625.a
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S. A. Grossman, J. Olson, T. Batchelor, D. Peereboom, G. Lesser, S. Desideri, X. Ye, T. Hammour, J. G. Supko, and for the New Approaches to Brain Tumor Therapy CNS Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma Neuro-oncol, April 1, 2008; 10(2): 190 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Carson, S. A. Grossman, J. D. Fisher, and E. G. Shaw Prognostic Factors for Survival in Adult Patients With Recurrent Glioma Enrolled Onto the New Approaches to Brain Tumor Therapy CNS Consortium Phase I and II Clinical Trials J. Clin. Oncol., June 20, 2007; 25(18): 2601 - 2606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Gore, S. Baylin, E. Sugar, H. Carraway, C. B. Miller, M. Carducci, M. Grever, O. Galm, T. Dauses, J. E. Karp, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res., June 15, 2006; 66(12): 6361 - 6369. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
